Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure

Journal of Infectious Diseases

Volumn 210, Issue 1, 2014, Pages 146-153

  Dorlo, Thomas P C ^a   Rijal, Suman ^d   Ostyn, Bart ^e   De Vries, Peter J ^b   Singh, Rupa ^d   Bhattarai, Narayan ^d   Uranw, Surendra ^d   Dujardin, Jean Claude ^e   Boelaert, Marleen ^e   Beijnen, Jos H ^c   Huitema, Alwin D R ^c  

^a UTRECHT UNIVERSITY   (Netherlands)

^b Tergooi Ziekenhuizen   (Netherlands)

^c SLOTERVAART HOSPITAL   (Netherlands)

^d B P KOIRALA INSTITUTE OF HEALTH SCIENCES   (Nepal)

^e INSTITUTE OF TROPICAL MEDICINE   (Belgium)

Author keywords

Exposure effect relationship; Leishmania; Modeling; Pharmacodynamics; Pharmacokinetics; Pharmacometrics; Population PK PD; Visceral leishmaniasis

Indexed keywords

MILTEFOSINE;

ADOLESCENT; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CHILD; COHORT ANALYSIS; DISEASE ASSOCIATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG EXPOSURE; DRUG TREATMENT FAILURE; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; PHARMACODYNAMICS; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; TREATMENT DURATION; VISCERAL LEISHMANIASIS;

ADOLESCENT; ADULT; AGED; ANTIPROTOZOAL AGENTS; BLOOD CHEMICAL ANALYSIS; CHILD; CHILD, PRESCHOOL; CHROMATOGRAPHY, LIQUID; HUMANS; INFANT; LEISHMANIASIS, VISCERAL; MALE; MIDDLE AGED; NEPAL; PHOSPHORYLCHOLINE; TANDEM MASS SPECTROMETRY; TREATMENT FAILURE; YOUNG ADULT;

EID: 84903272959     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu039     Document Type: Article

References (32)

1. Dorlo TPC, Balasegaram M, Beijnen JH, de Vries PJ. Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. J Antimicrob Chemother 2012; 67:2576-97.
2. Sundar S, Jha TK, Thakur CP, et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 2002; 347:1739-46.
3. Mondal D, Singh SP, Kumar N, et al. Visceral leishmaniasis elimination programme in India, Bangladesh, and Nepal: reshaping the case finding/ case management strategy. PLoS Negl Trop Dis 2009; 3:e355.
4. Joshi A, Narain JP, Prasittisuk C, et al. Can visceral leishmaniasis be eliminated from Asia? J Vector Borne Dis 2008; 45:105-111.
5. World Health Organization Regional Office for South-East Asia. In: Programme manager's meeting on elimination of Kala-azar in the South-East Asia Region, Faridabad, Haryana, India, 17-19 February 2009. 2010. Available at: http://apps.searo.who.int/pds-docs/B4518.pdf. Accessed 10 February 2014.
6. World Health Organization Regional Office for South-East Asia. In: Regional Technical Advisory Group on Kala-azar Elimination - report of the second meeting, Kathmandu, Nepal, 30 October-2 November 2006. 2007. Available at: http://209.61.208.233/LinkFiles/Kala-azar-VBC-93.pdf. Accessed 10 February 2014.
7. Sundar S, Singh A, Rai M, et al. Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use. Clin Infect Dis 2012; 55:543-50.
8. Rijal S, Ostyn B, Uranw S, et al. Increasing failure of miltefosine in the treatment of kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance. Clin Infect Dis 2013; 56: 1530-8.
9. Dorlo TPC, van Thiel PPAM, Huitema ADR, et al. Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients. Antimicrob Agents Chemother 2008; 52:2855-60.
10. Dorlo TPC, Huitema ADR, Beijnen JH, de Vries PJ. Optimal dosing of miltefosine in children and adults with visceral leishmaniasis. Antimicrob Agents Chemother 2012; 56:3864-72.
11. Davies GR, Hope W, Khoo S. Opinion: The Pharmacometrics of Infectious Disease. CPT: Pharmacomet Syst Pharmacol 2013; 2:e70.
12. Ette EI, Williams PJ. Pharmacometrics: the science of quantitative pharmacology, 1st ed. Hoboken, New Jersey: John Wiley & Sons, Inc., 2007.
13. Stone JA, Banfield C, Pfister M, et al. Model-based drug development survey finds pharmacometrics impacting decision making in the pharmaceutical industry. J Clin Pharmacol 2010; 50(9 Suppl):20S-30S.
14. Marshall SF, Hemmings R, Josephson F, Karlsson MO, Posch M, Steimer J-L. Modeling and simulation to optimize the design and analysis of confirmatory trials, characterize risk-benefit, and support label claims. CPT: Pharmacomet Syst Pharmacol 2013; 2:e27.
15. Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. Quantification of lean bodyweight. Clin Pharmacokinet 2005; 44: 1051-65.
16. Uranw S, Ostyn B, Dorlo TPC, et al. Adherence to miltefosine treatment for visceral leishmaniasis under routine conditions in Nepal. Trop Med Int Health 2013; 18:179-87.
17. Dorlo TPC, Hillebrand MJX, Rosing H, Eggelte TA, de Vries PJ, Beijnen JH. Development and validation of a quantitative assay for the measurement of miltefosine in human plasma by liquid chromatographytandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 865:55-62.
18. Beal SL, Boeckmann AJ, Sheiner LB. NONMEM users guides. Ellicott City, MD: Icon Development Solutions, 2006.
19. R Development Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2011.
20. Lindbom L, Pihlgren P, Jonsson EN, Jonsson N. PsN-Toolkit-a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed 2005; 79:241-57.
21. Lindbom L, Ribbing J, Jonsson EN. Perl-speaks-NONMEM (PsN)- a Perl module for NONMEM related programming. Comput Methods Programs Biomed 2004; 75:85-94.
22. Keizer RJ, van Benten M, Beijnen JH, Schellens JHM, Huitema ADR. Piraña and PCluster: a modeling environment and cluster infrastructure for NONMEM. Comput Methods Programs Biomed 2011; 101:72-9.
23. Jha TK, Sundar S, Thakur CP, et al. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J Med 1999; 341: 1795-800.
24. Sundar S, Jha TK, Sindermann H, Junge K, Bachmann P, Berman J. Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis. Pediatr Infect Dis J 2003; 22:434-8.
25. Savic RM, Karlsson MO. Importance of shrinkage in empirical Bayes estimates for diagnostics: problems and solutions. AAPS J 2009; 11:558-69.
26. Bhandari V, Kulshrestha A, Deep DK, et al. Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post Kala-Azar dermal leishmaniasis. PLoS Negl Trop Dis 2012; 6:e1657.
27. Stauch A, Sarkar RR, Picado A, et al. Visceral leishmaniasis in the Indian subcontinent: modelling epidemiology and control. PLoS Negl Trop Dis 2011; 5:e1405.
28. Paris C, Loiseau PM, Bories C, Bréard J. Miltefosine induces apoptosislike death in Leishmania donovani promastigotes. Antimicrob Agents Chemother 2004; 48:852-9.
29. Rakotomanga M, Blanc S, Gaudin K, Chaminade P, Loiseau PM. Miltefosine affects lipid metabolism in Leishmania donovani promastigotes. Antimicrob Agents Chemother 2007; 51:1425-30.
30. Sundar S, Makharia A, More DK, et al. Short-course of oral miltefosine for treatment of visceral leishmaniasis. Clin Infect Dis 2000; 31:1110-3.
31. Rijal S, Yardley V, Chappuis F, et al. Antimonial treatment of visceral leishmaniasis: are current in vitro susceptibility assays adequate for prognosis of in vivo therapy outcome? Microbes Infect 2007; 9:529-35.
32. Sengupta PC. History of kala-azar in India. Indian Med Gaz 1947; 82:281-6.